MCID: BRN071
MIFTS: 49

Brain Injury

Categories: Neuronal diseases

Aliases & Classifications for Brain Injury

MalaCards integrated aliases for Brain Injury:

Name: Brain Injury 53 37

Classifications:



Summaries for Brain Injury

NINDS : 53 Traumatic brain injury (TBI), a form of acquired brain injury, occurs when a sudden trauma causes damage to the brain. TBI can result when the head suddenly and violently hits an object, or when an object pierces the skull and enters brain tissue.  Symptoms of a TBI can be mild, moderate, or severe, depending on the extent of the damage to the brain. A person with a mild TBI may remain conscious or may experience a loss of consciousness for a few seconds or minutes. Other symptoms of mild TBI include headache, confusion, lightheadedness, dizziness, blurred vision or tired eyes, ringing in the ears, bad taste in the mouth, fatigue or lethargy, a change in sleep patterns, behavioral or mood changes, and trouble with memory, concentration, attention, or thinking.  A person with a moderate or severe TBI may show these same symptoms, but may also have a headache that gets worse or does not go away, repeated vomiting or nausea, convulsions or seizures, an inability to awaken from sleep, dilation of one or both pupils of the eyes, slurred speech, weakness or numbness in the extremities, loss of coordination, and increased confusion, restlessness, or agitation.

MalaCards based summary : Brain Injury is related to neonatal hypoxic and ischemic brain injury and head injury. An important gene associated with Brain Injury is TMEM158 (Transmembrane Protein 158), and among its related pathways/superpathways are Parkinson disease and Neuroscience. The drugs Diclofenac and Cisatracurium have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and heart, and related phenotypes are behavior/neurological and homeostasis/metabolism

Related Diseases for Brain Injury

Diseases related to Brain Injury via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 981)
# Related Disease Score Top Affiliating Genes
1 neonatal hypoxic and ischemic brain injury 34.3 MBP ENO2 BDNF
2 head injury 33.4 S100B ENO2 APOE
3 persistent vegetative state 32.9 ENO2 APOE
4 periventricular leukomalacia 32.6 MBP IL6 EPO
5 post-cardiac arrest syndrome 32.4 S100B IL6 ENO2
6 cerebral hypoxia 32.4 IGF1 CASP3
7 normal pressure hydrocephalus 32.0 IGF1 GFAP BDNF APOE
8 traumatic brain injury 31.8 UCHL1 S100B MBP IL6 IGF1 GFAP
9 amnestic disorder 31.6 S100B DRD2 BDNF APOE
10 speech and communication disorders 31.6 IL6 DRD2 COMT BDNF APOE
11 dementia 31.3 UCHL1 GFAP DRD2 COMT BDNF APOE
12 cardiac arrest 31.2 S100B EPO ENO2 ENO1 APOE
13 obsessive-compulsive disorder 31.1 IL6 IGF1 DRD2 COMT BDNF APOE
14 post-traumatic stress disorder 31.1 DRD2 COMT BDNF APOE
15 spinal cord injury 31.1 IL6 GFAP CASP3 BDNF
16 carotid artery occlusion 31.0 MBP GFAP CASP3
17 cerebral palsy 30.8 S100B IL6 IGF1 BDNF APOE
18 mental depression 30.6 IL6 DRD2 COMT BDNF
19 generalized anxiety disorder 30.5 DRD2 COMT BDNF
20 status epilepticus 30.5 GFAP ENO2 DRD2 CASP3 BDNF
21 personality disorder 30.5 DRD2 COMT BDNF
22 anxiety 30.4 IL6 DRD2 COMT BDNF APOE
23 akinetic mutism 30.4 S100B MBP ENO2
24 alzheimer disease 30.4 UCHL1 S100B IL6 GFAP DRD2 COMT
25 sleep disorder 30.4 IL6 IGF1 DRD2 BDNF APOE
26 mood disorder 30.4 IL6 GFAP DRD2 COMT BDNF
27 alexithymia 30.4 IL6 DRD2 COMT
28 asphyxia neonatorum 30.3 S100B IL6 EPO ENO2 CASP3
29 psychotic disorder 30.3 S100B DRD2 COMT BDNF
30 sleep apnea 30.3 IL6 IGF1 EPO BDNF APOE
31 leukoencephalopathy, hereditary diffuse, with spheroids 30.2 S100B MBP GFAP
32 major depressive disorder 30.2 IL6 DRD2 COMT BDNF APOE
33 stroke, ischemic 30.2 MBP IL6 ENO2 CASP3 BDNF APOE
34 chiari malformation 30.1 MBP GFAP
35 fetal alcohol syndrome 30.1 GFAP CASP3 BDNF
36 central nervous system disease 30.0 MBP IL6 GFAP BDNF APOE
37 ganglioglioma 30.0 S100B GFAP ENO2
38 migraine with or without aura 1 30.0 S100B IL6 DRD2 COMT BDNF APOE
39 optic nerve disease 30.0 MBP IL6 GFAP BDNF
40 disease of mental health 30.0 IL6 DRD2 COMT BDNF APOE
41 attention deficit-hyperactivity disorder 29.9 S100B IL6 DRD2 COMT BDNF
42 prion disease 29.9 GFAP ENO2 APOE
43 benign ependymoma 29.9 S100B GFAP ENO2
44 substance dependence 29.9 IL6 DRD2 COMT BDNF
45 endogenous depression 29.8 IL6 COMT BDNF
46 vascular disease 29.8 IL6 IGF1 EPO CASP3 APOE
47 hepatic encephalopathy 29.8 S100B IL6 DRD2
48 scrapie 29.8 GFAP ENO2 APOE
49 borderline personality disorder 29.8 DRD2 COMT BDNF
50 apnea, obstructive sleep 29.8 IL6 IGF1 APOE

Graphical network of the top 20 diseases related to Brain Injury:



Diseases related to Brain Injury

Symptoms & Phenotypes for Brain Injury

MGI Mouse Phenotypes related to Brain Injury:

45 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.38 APOE ASIC1 BDNF CASP3 CCR2 COMT
2 homeostasis/metabolism MP:0005376 10.31 APOE BDNF CASP3 CCR2 COMT CXCL10
3 cellular MP:0005384 10.29 APOE BDNF CASP3 CCR2 CXCL10 DRD2
4 growth/size/body region MP:0005378 10.29 APOE BDNF CASP3 CCR2 DRD2 ENO1
5 cardiovascular system MP:0005385 10.26 APOE CASP3 CCR2 COMT CXCL10 DRD2
6 hematopoietic system MP:0005397 10.23 APOE CASP3 CCR2 COMT CXCL10 DRD2
7 immune system MP:0005387 10.18 APOE CASP3 CCR2 COMT CXCL10 DRD2
8 mortality/aging MP:0010768 10.17 APOE BDNF CASP3 CCR2 CXCL10 DRD2
9 nervous system MP:0003631 10.13 APOE ASIC1 BDNF CASP3 CCR2 COMT
10 digestive/alimentary MP:0005381 10.1 APOE BDNF CASP3 CCR2 DRD2 GFAP
11 integument MP:0010771 10.02 APOE BDNF CASP3 DRD2 EPO IGF1
12 renal/urinary system MP:0005367 9.76 APOE CASP3 CCR2 COMT DRD2 IGF1
13 respiratory system MP:0005388 9.7 APOE BDNF CASP3 CCR2 COMT DRD2
14 taste/olfaction MP:0005394 9.02 APOE BDNF CASP3 DRD2 ENO2

Drugs & Therapeutics for Brain Injury

Drugs for Brain Injury (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 554)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
2
Cisatracurium Approved Phase 4 96946-41-7
3
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
4
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
5
Quinidine Approved, Investigational Phase 4 56-54-2 441074
6
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
7
Testosterone enanthate Approved Phase 4 315-37-7 9416
8
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 10204 6013
9
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
10
Methyltestosterone Approved Phase 4 58-18-4 6010
11
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
12
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
13
Thiopental Approved, Vet_approved Phase 4 76-75-5 3000715
14
Citalopram Approved Phase 4 59729-33-8 2771
15
Sertraline Approved Phase 4 79617-96-2 68617
16
Fosphenytoin Approved, Investigational Phase 4 93390-81-9 56339
17
Phenylephrine Approved Phase 4 59-42-7 6041
18
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
19
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
20
Simvastatin Approved Phase 4 79902-63-9 54454
21
Dextromethorphan Approved Phase 4 125-71-3 5360696 5362449
22
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
23
Nicotine Approved Phase 4 54-11-5 942 89594
24
Caffeine Approved Phase 4 58-08-2 2519
25
Haloperidol Approved Phase 4 52-86-8 3559
26
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
27
Histamine Approved, Investigational Phase 4 51-45-6 774
28
Mirtazapine Approved Phase 4 85650-52-8, 61337-67-5 4205
29
Pseudoephedrine Approved Phase 4 90-82-4 7028
30
Ephedrine Approved Phase 4 299-42-3 9294
31
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
32
Prazosin Approved Phase 4 19216-56-9 4893
33
Sargramostim Approved, Investigational Phase 4 83869-56-1, 123774-72-1
34
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
35
Propranolol Approved, Investigational Phase 4 525-66-6 4946
36
Topiramate Approved Phase 4 97240-79-4 5284627
37
Levetiracetam Approved Phase 4 102767-28-2 441341
38
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
39
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
40
Donepezil Approved Phase 4 120014-06-4 3152
41
Rotigotine Approved Phase 4 99755-59-6, 92206-54-7 57537
42
Amitriptyline Approved Phase 4 50-48-6 2160
43
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
44
Rizatriptan Approved Phase 4 144034-80-0, 145202-66-0 5078
45
Pramipexole Approved, Investigational Phase 4 104632-26-0 119570 59868
46
Zolmitriptan Approved, Investigational Phase 4 139264-17-8 441240 60857
47
Amantadine Approved Phase 4 768-94-5 2130
48
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
49
Buspirone Approved, Investigational Phase 4 36505-84-7 2477
50
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0

Interventional clinical trials:

(show top 50) (show all 2294)
# Name Status NCT ID Phase Drugs
1 Randomized Controlled Clinical Study of Intensive Versus Nonintensive Insulin Therapy for Hyperglycemia After Traumatic Brain Injury Unknown status NCT02161055 Phase 4 Insulin
2 A Clinical Trial of the Effect of Midazolam on the Cerebral Metabolism and Inflammatory Response in Patients With Moderate and Severe Traumatic Brain Injury Unknown status NCT02071407 Phase 4 Midazolam;Placebo
3 A Randomised Control Trial to Determine the Effectiveness of Sensory Stimulation Program in Reducing the Length of Time Spent by Severely Brain Injured Patients in a Vegetative State in the Acute Hospital Environment Unknown status NCT00163878 Phase 4
4 Normothermia in Patients With Acute Cerebral Damage Unknown status NCT00491192 Phase 4 Diclofenac
5 A Randomized Controlled Trial of Antidepressant Maintenance for Major Depression Following Mild Traumatic Brain Injury Unknown status NCT00162916 Phase 4 citalopram;Placebo
6 Treatment of Intracranial Hypertension of Severe Tramatic Brain Injured Patients. Physiopathologic Effects of Neuromuscular Blocking Agents. A Controlled Randomized Study Versus Placebo Unknown status NCT02404779 Phase 4 cisatracurium besilate
7 Pilot Study: The Effect of Rozerem on Sleep Disturbance After Traumatic Brain Injury Unknown status NCT01207050 Phase 4 Ramelteon
8 Effects of Intensive Insulin Therapy on Mortality, Morbidity and Long Term Neurologic Outcome in Neurosurgical Intensive Care Patients Unknown status NCT00505505 Phase 4 Insulin (Actrapid)
9 Citicholine-Amantadine Trial in Traumatic Brain Injury Unknown status NCT03430817 Phase 4 Citicholine;Amantadine
10 Dopamine Treatment in Children With Cerebral Palsy With Dystonia- A Double Blind Controlled Study Unknown status NCT01361373 Phase 4 L- DOPA;placebo
11 The Benefit of Prophylactic Anticonvulsant in Post Cardiac Arrest Syndrome With Induced Mild Hypothermia Unknown status NCT01083784 Phase 4 Use of prophylactic anticonvulsants (valproate, clonazepam);Control group
12 Administration of Tranexamic Acid in the Preclinical Setting and Its Effect on Coagulation Parameters and Outcome in Multiple Trauma Patients and Isolated TBI in EMS (Schutz Und Rettung Zürich) and Helicopter Rescue(REGA). Unknown status NCT02354885 Phase 4 Tranexamic Acid
13 Efficiency and Tolerance of a Small-peptide Enteral Feeding Formula Compared to a Whole-protein Formula in the Critically Ill Patient : a Prospective Randomized Trial Unknown status NCT01833624 Phase 4
14 Gastrodin Prevents Cognitive Decline Related to Cardiopulmonary Bypass Unknown status NCT00297245 Phase 4 cognitive function
15 Efficacy of Creative Therapy for Stroke Patients Unknown status NCT01455155 Phase 4
16 Does Discontinuation of Aspirin Treatment Following Head Trauma Decrease the Incidence of Chronic Subdural Hematoma? Unknown status NCT01470040 Phase 4 discontinuation of aspirin therapy;continuation of aspirin therapy
17 The Use of Low Molecular Weight Heparin in Traumatic Brain Injury Completed NCT00170378 Phase 4 Enoxaparin
18 Efficacy of Methylphenidate for Management of Long-Term Attention Problems After Pediatric Traumatic Brain Injury (TBI) Completed NCT01933217 Phase 4 Methylphenidate;Placebo
19 Pharmacological Intervention in Depression After Traumatic Brain Injury (A Research Study Within the Traumatic Brain Injury Model System) Completed NCT00205491 Phase 4 Venlafaxine
20 A 26-Week Open-Label Extension to Protocol No. CENA713BUS11: A 12-Week, Prospective, Double-blind, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Rivastigmine 3 to 6 mg/Day in Patients With Traumatic Brain Injury (TBI) With Persistent Cognitive Deficits Completed NCT00219245 Phase 4 Rivastigmine
21 Intravenous Exenatide Infusion in Critically Ill Patients With Acute Brain Injury Completed NCT02058940 Phase 4 Exenatide
22 Improvement of Therapy in Patients With Severe Traumatic Brain Injury: Differential Impact of Local and Systemic Changes and Routinely Applied Drugs Completed NCT02130674 Phase 4 Dipeptiven
23 Anterior Pituitary Hormone Replacement in Traumatic Brain Injury Completed NCT00957671 Phase 4 Recombinant human growth hormone
24 Treatment Outcomes With Lisdexamfetamine Dimesylate (Vyvanse) in Children With Traumatic Brain Injury-Related Attention Deficits Completed NCT02712996 Phase 4 Lisdexamfetamine;Placebo
25 Topiramate Treatment of Hazardous and Harmful Alcohol Use in Veterans With TBI Completed NCT01750268 Phase 4 Topiramate;Placebo
26 Effect of Erythropoietin on Preterm Brain Injury Completed NCT02036073 Phase 4 recombinant human erythropoietin
27 Beta-Adrenergic Blockade for Suppression of Catecholamine Surge Following Traumatic Brain Injury: A Randomized Trial Completed NCT02957331 Phase 4 Propranolol
28 Using Propranolol in Traumatic Brain Injury to Reduce Sympathetic Storm Phenomenon: A Prospective Randomized Clinical Trial Injury to Reduce Sympathetic Storm Phenomenon: A Prospective Randomized Clinical Trial Completed NCT03401515 Phase 4 Propranolol Hydrochloride 1 MG/ML
29 Equimolar Doses of Mannitol and Hypertonic Saline in the Treatment of Elevated Intracranial Pressure Completed NCT00447018 Phase 4 20% mannitol;7.45% hypertonic saline solution
30 Neuroendocrine Dysfunction in Traumatic Brain Injury: Effects of Testosterone Therapy Completed NCT01201863 Phase 4 Androgel (Testosterone Gel);Androgel Placebo
31 Simvastatin: Proof-of-Concept for Prevention of Neurodegeneration in Mild TBI Completed NCT01952288 Phase 4 simvastatin;Placebo Oral Tablet
32 Assessment of Seizure Prophylaxis Protocols Using Intravenous Levetiracetam in a Neuroscience Intensive Care Unit Completed NCT00618436 Phase 4 Levetiracetam;Phenytoin
33 A Study to Assess the Safety, Tolerability and Effectiveness of Nuedexta (Dextromethorphan 20 mg/Quinidine 10 mg) in the Treatment of Pseudobulbar Affect (PBA) Completed NCT01799941 Phase 4 Nuedexta (DM 20 mg/Q 10 mg)
34 Phase IV Study of Cognitive Rehabilitation Effectiveness for Mild Traumatic Brain Injury Completed NCT01339806 Phase 4
35 Amantadine Hydrochloride for Treatment of Symptoms of the Post-traumatic Confusional State Among Neurorehabilitation Admissions With TBI: A Randomized, Double-Blind, Placebo-Controlled Trial Completed NCT00693121 Phase 4 Amantadine hydrochloride;Placebo capsule
36 The Control of Brain Networks After Traumatic Brain Injury: a Neuroimaging and Neuropsychological Study of Dopamine and Cognition Completed NCT02015949 Phase 4 Methylphenidate;Placebo
37 Pediatric Traumatic Brain Injury: Methylphenidate Effects on Early Recovery Completed NCT00035139 Phase 4 methylphenidate
38 The Serotonin Transporter Gene Polymorphism and Major Depression Following Traumatic Brain Injury Completed NCT00254007 Phase 4 citalopram (celexa)
39 Bispectral Index Value Changes During Induction and Surgical Decompression in Head Injury Patients Completed NCT03480880 Phase 4
40 Abobotulinumtoxina Efficacy in Post-Traumatic Headache Completed NCT03928496 Phase 4 AbobotulinumtoxinA;Normal saline
41 Micronized Oral Progesterone and Effect on Time Symptomatic From Concussion: A Pilot Study Completed NCT01809639 Phase 4 Progesterone;Placebo
42 Comparative Efficacy of Three Preparations of Botox-A in Treating Spasticity Completed NCT00178646 Phase 4 Botox
43 Video and Temporal Spatial Parameters Assessment of Gait After Dysport Treatment. A Pilot Study Completed NCT03501043 Phase 4 Dysport
44 Magnetic Resonance Imaging and Neurodevelopmental Outcomes in Preterm Infants Following Administration of High-Dose Caffeine - A Pilot Study Completed NCT00809055 Phase 4 Caffeine citrate
45 Clinical Interest of Endovascular Cooling in the Management of Cardiac Arrest: Impact on Mortality in a Randomized Medico-economical Trial (the ICEREA Study) Completed NCT00392639 Phase 4
46 An Open-Label Trial of Memantine for Cognitive Impairment in Patients With Post-Traumatic Stress Disorder Completed NCT02258828 Phase 4 Memantine;Placebo
47 The Effect of Amantadine on Movement Disorder in Ataxia-Telangiectasia Completed NCT00950196 Phase 4 amantadine sulphate
48 Progesterone Augmentation of Nicotine Replacement Therapy Study Completed NCT02685072 Phase 4 Progesterone (200 mgs BID);Placebo
49 Dexmedetomidine Addition to Benzodiazepines for Patients With Alcohol Withdrawal Syndrome in the ICU: a Randomised Controlled Study Completed NCT02496650 Phase 4 Dexmedetomidine
50 Restrictive vs. Liberal Oxygen Therapy for Trauma Patients. PILOT: The TRAUMOX Trial Completed NCT03491644 Phase 4 Titrated Oxygen;Liberal Oxygen

Search NIH Clinical Center for Brain Injury

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Brain Injury cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Brain Injury:
Hematopoietic stem cells for treatment of ischemic brain injury
Embryonic/Adult Cultured Cells Related to Brain Injury:
Bone marrow-derived hematopoietic stem cells (family)

Genetic Tests for Brain Injury

Anatomical Context for Brain Injury

MalaCards organs/tissues related to Brain Injury:

40
Brain, Testes, Heart, Bone, Cortex, Spinal Cord, Eye

Publications for Brain Injury

Articles related to Brain Injury:

(show top 50) (show all 30000)
# Title Authors PMID Year
1
RVG29-modified microRNA-loaded nanoparticles improve ischemic brain injury by nasal delivery. 61
32400219 2020
2
Acute effects of human protein S administration after traumatic brain injury in mice. 61
32394965 2020
3
Injury of the dentatorubrothalamic tract in patients with post-traumatic tremor following mild traumatic brain injury: a case-control study. 61
32394963 2020
4
Sestrin2 promotes angiogenesis to alleviate brain injury by activating Nrf2 through regulating the interaction between p62 and Keap1 following photothrombotic stroke in rats. 61
32526292 2020
5
Impaired cerebral blood flow regulation in chronic traumatic brain injury. 61
32505751 2020
6
Corrigendum: Resveratrol reduces brain injury after subarachnoid hemorrhage by inhibiting oxidative stress and endoplasmic reticulum stress. 61
32209777 2020
7
Effects of seawater immersion on open traumatic brain injury in rabbit model. 61
32445716 2020
8
The pathologic outcomes and efficacy of epothilone treatment following traumatic brain injury is determined by age. 61
32480164 2020
9
The single intravenous administration of methylene blue after traumatic brain injury diminishes neurological deficit, blood-brain barrier disruption and decrease in the expression of S100 protein in rats. 61
32339501 2020
10
Midazolam contributes to neuroprotection against hypoxia/reoxygenation-induced brain injury in neonatal rats via regulation of EAAT2. 61
32433937 2020
11
Progesterone treatment following traumatic brain injury in the 11-day-old rat attenuates cognitive deficits and neuronal hyperexcitability in adolescence. 61
32335121 2020
12
Long-term beneficial effects of hematopoietic growth factors on brain repair in the chronic phase of severe traumatic brain injury. 61
32360282 2020
13
TMT-based proteomics analysis reveals the protective effects of Xuefu Zhuyu decoction in a rat model of traumatic brain injury. 61
32298754 2020
14
Isoflurane versus sevoflurane for early brain injury and expression of sphingosine kinase 1 after experimental subarachnoid hemorrhage. 61
32522601 2020
15
Delirium prevalence and prevention in patients with acute brain injury: A prospective before-and-after intervention study. 61
32089416 2020
16
Modulating neuroinflammation and oxidative stress to prevent epilepsy and improve outcomes after traumatic brain injury. 61
31837825 2020
17
Epidemiology of traumatic brain injury-associated epilepsy in western China: An analysis of multicenter data. 61
32438297 2020
18
Spermidine Exhibits Protective Effects Against Traumatic Brain Injury. 61
31916070 2020
19
Cathepsin B in neurodegeneration of Alzheimer's disease, traumatic brain injury, and related brain disorders. 61
32305689 2020
20
Neuroregenerative and protective functions of Leukemia Inhibitory Factor in perinatal hypoxic-ischemic brain injury. 61
32320698 2020
21
γ' fibrinogen levels are associated with blood clot strength in traumatic brain injury patients. 61
31948701 2020
22
Disparity in discharging elderly traumatic brain injury patients to rehabilitation centers based on trauma center level. 61
32370875 2020
23
TGFβ1 alleviates axonal injury by regulating microglia/macrophages alternative activation in traumatic brain injury. 61
32389801 2020
24
D-dimer/fibrinogen ratio for the prediction of progressive hemorrhagic injury after traumatic brain injury. 61
32333859 2020
25
Mouse Bone Marrow-Derived Mesenchymal Stem Cells Alleviate Perinatal Brain Injury Via a CD8+ T Cell Mechanism in a Model of Intrauterine Inflammation. 61
31997258 2020
26
Identification of adverse events in pediatric severe traumatic brain injury patients to target evidence-based prevention for increased performance improvement and patient safety. 61
32446657 2020
27
Establishing the Factor Structure of a Health-Related Quality of Life Measurement System for Caregivers of Persons Living With Traumatic Brain Injury. 61
32315649 2020
28
Associations between coping style, illness perceptions and self-reported symptoms after mild traumatic brain injury in prospectively studied pre-morbidly healthy individuals. 61
30560733 2020
29
Relationship continuity and person-centred care: An exploratory mixed-methods investigation of spousal partners' responses to the challenging care needs of those with acquired brain injury. 61
30642233 2020
30
Corrigendum to "Ghrelin attenuates secondary brain injury following intracerebral hemorrhage by inhibiting NLRP3 inflammasome activation and promoting Nrf2/ARE signaling pathway in mice" [Int. Immunopharmacol. 79 (2020) 106180]. 61
32278662 2020
31
Mitochondrial damage & lipid signaling in traumatic brain injury. 61
32289317 2020
32
Fast-tracking regenerative medicine for traumatic brain injury. 61
31960797 2020
33
Early cerebrovascular and long-term neurological modifications ensue following juvenile mild traumatic brain injury in male mice. 61
32442681 2020
34
Ageing and genetic background influence anaesthetic effects in a D. melanogaster model of blunt trauma with brain injury†. 61
32466842 2020
35
The role of a lncRNA (TCONS_00044595) in regulating pineal CLOCK expression after neonatal hypoxia-ischemia brain injury. 61
32448507 2020
36
Blood-based biomarkers for prediction of intracranial hemorrhage and outcome in patients with moderate or severe traumatic brain injury. 61
32251265 2020
37
Multimodal imaging of hair follicle bulge-derived stem cells in a mouse model of traumatic brain injury. 61
32036485 2020
38
In Reply: Blood Pressure Variability and Optimal Cerebral Perfusion Pressure-New Therapeutic Targets in Traumatic Brain Injury. 61
32294197 2020
39
Improvement of quality of life (QOL) between 1 and 3-4 years after traumatic brain injury (TBI) in ICU patients. 61
32405669 2020
40
Triglyceride is a Good Biomarker of Increased Injury Severity on a High Fat Diet Rat After Traumatic Brain Injury. 61
32222876 2020
41
Participation in competitive employment after severe traumatic brain injury: New employment versus return to previous (pre-injury) employment. 61
30404583 2020
42
The reliability of evaluating conversations between people with traumatic brain injury and their communication partners via videoconferencing. 61
30520702 2020
43
Inhibiting the interaction between apoptosis-inducing factor and cyclophilin A prevents brain injury in neonatal mice after hypoxia-ischemia. 61
32277944 2020
44
The Effect of Age and Pain on Quantitative Sensory Testing Measurements After Moderate-to-Severe Traumatic Brain Injury: Preliminary Findings. 61
32208852 2020
45
Low-pressure fluid percussion minimally adds to the sham craniectomy-induced neurobehavioral changes: Implication for experimental traumatic brain injury model. 61
32240659 2020
46
Moderate/severe traumatic brain injury as a trigger of chronic neurodegeneration in humans. 61
31960805 2020
47
Risk factors for corticosteroid insufficiency during the sub-acute phase of acute traumatic brain injury. 61
31960811 2020
48
Use and Removal of Inferior Vena Cava Filters in Patients With Acute Brain Injury. 61
32549942 2020
49
Fatigue, Participation and Quality of Life in Adolescents and Young Adults with Acquired Brain Injury in an Outpatient Rehabilitation Cohort. 61
31746261 2020
50
Hippotherapy in adults with acquired brain injury: A systematic review. 61
30015542 2020

Variations for Brain Injury

Expression for Brain Injury

Search GEO for disease gene expression data for Brain Injury.

Pathways for Brain Injury

GO Terms for Brain Injury

Cellular components related to Brain Injury according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.81 S100B IL6 IGF1 EPO ENO2 ENO1
2 dendrite GO:0030425 9.65 DRD2 COMT CCR2 BDNF APOE
3 cell body GO:0044297 9.5 GFAP EPO COMT
4 neuronal cell body GO:0043025 9.17 UCHL1 S100B MBP ENO2 CCR2 CASP3
5 phosphopyruvate hydratase complex GO:0000015 8.96 ENO2 ENO1

Biological processes related to Brain Injury according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.92 S100B IL6 IGF1 EPO CXCL10
2 negative regulation of apoptotic process GO:0043066 9.91 IL6 IGF1 EPO CASP3 BDNF
3 response to lipopolysaccharide GO:0032496 9.71 EPO CXCL10 COMT CASP3
4 response to wounding GO:0009611 9.67 GFAP CCR2 CASP3
5 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.65 IL6 IGF1 EPO
6 response to glucocorticoid GO:0051384 9.63 S100B IL6 CASP3
7 learning or memory GO:0007611 9.61 S100B CASP3 BDNF
8 negative regulation of amyloid-beta formation GO:1902430 9.54 IGF1 APOE
9 long-term synaptic potentiation GO:0060291 9.43 SLC24A2 S100B GFAP
10 regulation of neurotransmitter uptake GO:0051580 9.37 GFAP DRD2
11 regulation of vacuole fusion, non-autophagic GO:0032889 9.32 ENO2 ENO1
12 axon target recognition GO:0007412 9.16 UCHL1 BDNF
13 regulation of vascular endothelial growth factor production GO:0010574 8.96 IL6 CCR2
14 memory GO:0007613 8.92 SLC24A2 S100B BDNF ASIC1

Molecular functions related to Brain Injury according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.11 UCHL1 S100B MSI2 MBP IL6 IGF1
2 signaling receptor binding GO:0005102 9.35 S100B DRD2 CXCL10 BDNF APOE
3 phosphopyruvate hydratase activity GO:0004634 8.62 ENO2 ENO1

Sources for Brain Injury

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....